BeforeItsNews only exists through ads. We ask all patriots who appreciate the evil we expose and want to
help us savage the NWO with more Truth to disable your ad-blocker on our site only so we can grow and expose more evil! Funding
gives us more weapons! Thank you patriots! Oh and If you disable the Ad-blocker - on your deathbed you will receive total
consciousness. So you got that going for you...which is nice!
Human Genome Sciences HGSI Benlysta Development andStock TradingUpdate. StockMarketFunding.com
Biotech Release Update: Human Genome Sciences HGSI
Mario Marciano has been covering biotech start ups for over 20 years. The last biotech trades he was involved in include DNDN, HGSI, MLMN, OSIP, DNA, GENZ, CELG, AMLN, AMGN, BIIB, MRK, and LLY. Over the last 12 years he’s had his eyes on HGSI Human Genome Sciences.
Mario has followed the Benlysta trials and recent trading action in HGSI. StockMarketFunding.com will be conducting a special audit on HGSI Stock and how the big players on Wall Street already own the stock with 92.8% Institutional Ownership.
We will also look at why and what Wall Street has done to manipulate HGSI’s company stockprice in recent months. The rumors that have been wide spread and StockMarketFunding.com has covered all the trades through our live trading videos to prove how Wall Street can manipulate investors with untrue facts, fabricated headlines and blog posts.
Mario has clearly stated that these companies spend millions of dollars in research and development and lately HGSI had a vote of 13-2 approval for a new drug for lupus. The final extension date for possible approval 3-10-2010 will make a major breakthrough if approved.
We believe there will be many more new developments and this will lead to HGSI becoming a major player in biotechnology which will lead to HGSI becoming a new 21st century biotech leader in medicine.
SMF will be hosting special events and updating new developments for HGSI in 2011. SMF will be updating our global trading network through our live stock radio show and live trading videos.
HGSI is a prime buy out target for some of the leading companies the biotech sector as HGSI has clearly matured into the next leader.
Mario Marciano
StockMarketFunding.com
Adimab has made its name for assembling a high-profile roster of Big Pharma partners that use its technology to discover new antibody drugs. Today, the Lebanon, NH-based company is announcing a new batch of partners—Genentech, Eli Lilly (NYSE:LLY), and Human Genome Sciences (NASDAQ:HGSI)—which add greater heft to co-founder and CEO Tillman Gerngross’s argument that his firm has vastly improved the way antibody drugs are discovered.
Adimab, which co-founded by Gerngross and Dane Wittrup of MIT in 2007, says it has now struck 15 antibody discovery agreements, up from five at the end of last year. Not all of its partners have agreed to be named, but the firm’s yeast-based system for discovering fully human antibodies has now attracted collaborations with the U.S. drug giant Merck (NYSE:MRK), Novartis, Pfizer (NYSE:PFE), and Roche, in addition to the latest trio of partnerships being disclosed today.
Adimab’s collaborators are seeking an edge in the competitive field of antibody drug discovery, and the startup’s system has shown it can produce quality antibody candidates against specific disease targets in shorter timeframes than traditional methods. “They are all looking for something better and more competitive, and right now we are the ones that are offering that,” Gerngross says. Antibody therapies already generate about $25 billion in annual sales and the rate of growth in that market has outpaced that of traditional small molecule drugs.
With Genentech, Adimab now has a collaboration with the most successful developer of antibody drugs in the world, Gerngross says. The South San Francisco company, the U.S. unit of Switzerland-based Roche, markets some of the best-selling antibody drugs on the planet such as the blockbuster cancer treatments.
Before It’s News® is a community of individuals who report on what’s going on around them, from all around the world.
Anyone can join.
Anyone can contribute.
Anyone can become informed about their world.
"United We Stand" Click Here To Create Your Personal Citizen Journalist
Account Today, Be Sure To Invite Your Friends.
Lion’s Mane Mushroom
Mushrooms are having a moment. One fabulous fungus in particular, lion’s mane, may help improve memory, depression and anxiety symptoms. They are also an excellent source of nutrients that show promise as a therapy for dementia, and other neurodegenerative diseases. If you’re living with anxiety or depression, you may be curious about all the therapy options out there — including the natural ones.Our Lion’s Mane WHOLE MIND Nootropic Blend has been formulated to utilize the potency of Lion’s mane but also include the benefits of four other Highly Beneficial Mushrooms. Synergistically, they work together to Build your health through improving cognitive function and immunity regardless of your age. Our Nootropic not only improves your Cognitive Function and Activates your Immune System, But it benefits growth of Essential Gut Flora, further enhancing your Vitality.
Our Formula includes:
Lion’s Mane Mushrooms which Increase Brain Power through nerve growth, lessen anxiety, reduce depression, and improve concentration. Its an excellent adaptogen, promotes sleep and improves immunity.
Shiitake Mushrooms which Fight cancer cells and infectious disease, boost the immune system, promotes brain function, and serves as a source of B vitamins.
Maitake Mushrooms which regulate blood sugar levels of diabetics, reduce hypertension and boosts the immune system.
Reishi Mushrooms which Fight inflammation, liver disease, fatigue, tumor growth and cancer. They Improve skin disorders and soothes digestive problems, stomach ulcers and leaky gut syndrome.
Chaga Mushrooms which have anti-aging effects, boost immune function, improve stamina and athletic performance, even act as a natural aphrodisiac, fighting diabetes and improving liver function.